Published in Nephrol Dial Transplant on February 08, 2011
Diseases of the parathyroid gland in chronic kidney disease. Clin Exp Nephrol (2011) 0.92
The surgical management of renal hyperparathyroidism. Eur Arch Otorhinolaryngol (2011) 0.91
Renal phosphate loss in long-term kidney transplantation. Clin J Am Soc Nephrol (2011) 0.85
Phosphate and FGF-23 homeostasis after kidney transplantation. Nat Rev Nephrol (2015) 0.79
FGF23 and mineral metabolism in the early post-renal transplantation period. Pediatr Nephrol (2013) 0.79
FGF23 in kidney transplant: the strange case of Doctor Jekyll and Mister Hyde. Clin Kidney J (2016) 0.75
FGF23 is associated with early post-transplant hypophosphataemia and normalizes faster than iPTH in living donor renal transplant recipients: a longitudinal follow-up study. Clin Kidney J (2016) 0.75
Mineral and bone disorder after kidney transplantation. World J Transplant (2015) 0.75
Beneficial effects of preemptive kidney transplantation on calcium and phosphorus disorders in early post-transplant recipients. Clin Exp Nephrol (2014) 0.75
Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature (2006) 9.40
Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest (2004) 7.00
FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res (2003) 6.81
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res (2009) 5.24
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res (2014) 4.83
Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab (2002) 4.17
Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int (2010) 3.04
Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol (2004) 3.03
Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology (2002) 3.00
Evaluation of new acute kidney injury biomarkers in a mixed intensive care unit. Crit Care Med (2011) 2.68
Impaired flow-dependent control of vascular tone and remodeling in P2X4-deficient mice. Nat Med (2005) 2.59
FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun (2004) 2.52
Combination of two urinary biomarkers predicts acute kidney injury after adult cardiac surgery. Ann Thorac Surg (2012) 2.39
Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int (2005) 2.26
Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med (2008) 2.25
Epigenetic modulation of the renal β-adrenergic-WNK4 pathway in salt-sensitive hypertension. Nat Med (2011) 2.18
Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int (2009) 2.10
Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial (2013) 2.07
Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol (2005) 2.05
Hemoglobin is expressed by mesangial cells and reduces oxidant stress. J Am Soc Nephrol (2008) 1.99
Renal L-type fatty acid--binding protein in acute ischemic injury. J Am Soc Nephrol (2007) 1.98
Renal disease in the elderly and the very elderly Japanese: analysis of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol (2012) 1.95
Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension (2007) 1.93
Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis (2004) 1.93
Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. Lancet (2002) 1.89
QTL mapping of domestication-related traits in soybean (Glycine max). Ann Bot (2007) 1.85
Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension (2002) 1.83
The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction. Transplantation (2011) 1.82
A microRNA regulatory mechanism of osteoblast differentiation. Proc Natl Acad Sci U S A (2009) 1.80
Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int (2005) 1.78
Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial (2005) 1.78
Endoplasmic reticulum stress induces autophagy in renal proximal tubular cells. Nephrol Dial Transplant (2009) 1.76
Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res (2008) 1.75
Blockade of the nuclear factor-κB pathway in the endothelium prevents insulin resistance and prolongs life spans. Circulation (2012) 1.75
Urinary L-type fatty acid-binding protein as a new biomarker of sepsis complicated with acute kidney injury. Crit Care Med (2010) 1.74
Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension (2002) 1.73
Protective effect of potassium against the hypertensive cardiac dysfunction: association with reactive oxygen species reduction. Hypertension (2006) 1.71
Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis (2011) 1.69
Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan. Am J Kidney Dis (2012) 1.68
Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int (2002) 1.68
Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res (2009) 1.63
Importance of endothelial NF-κB signalling in vascular remodelling and aortic aneurysm formation. Cardiovasc Res (2012) 1.61
IRBIT, an inositol 1,4,5-trisphosphate receptor-binding protein, specifically binds to and activates pancreas-type Na+/HCO3- cotransporter 1 (pNBC1). Proc Natl Acad Sci U S A (2006) 1.61
Induction of renoprotective gene expression by cobalt ameliorates ischemic injury of the kidney in rats. J Am Soc Nephrol (2003) 1.60
siRNA-based therapy ameliorates glomerulonephritis. J Am Soc Nephrol (2010) 1.58
Retracted Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: a COOPERATE-ABP substudy. Am J Nephrol (2004) 1.57
A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab (2005) 1.56
Methylglyoxal induces peritoneal thickening by mesenchymal-like mesothelial cells in rats. Nephrol Dial Transplant (2008) 1.56
Effects of cinacalcet treatment on serum soluble Klotho levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant (2011) 1.55
Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension (2006) 1.55
Isolation and potential existence of side population cells in adult human kidney. Int J Urol (2008) 1.55
Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol (2014) 1.55
Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab (2004) 1.54
Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res (2007) 1.52
Evidence of tubular hypoxia in the early phase in the remnant kidney model. J Am Soc Nephrol (2004) 1.52
Renoprotective effect of erythropoietin against ischaemia-reperfusion injury in a non-human primate model. Nephrol Dial Transplant (2010) 1.52
Metallothionein is upregulated by hypoxia and stabilizes hypoxia-inducible factor in the kidney. Kidney Int (2008) 1.52
Antioxidant, EUK-8, prevents murine dilated cardiomyopathy. Circ J (2009) 1.52
Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells. J Am Soc Nephrol (2006) 1.51
Marked hypercalcemia in a patient with hypocalciuric hypercalcemia without a mutation in the calcium-sensing receptor gene. Intern Med (2002) 1.50
Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions. J Hypertens (2008) 1.49
Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol (2006) 1.49
Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone (2009) 1.47
Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract (2005) 1.46
Putative role of asymmetric dimethylarginine in microvascular disease of kidney and heart in hypertensive patients. Am J Hypertens (2008) 1.46
Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem (2006) 1.46
Ghrelin directly regulates bone formation. J Bone Miner Res (2004) 1.44
Parathyroid hormone-related protein induced coupled increases in bone formation and resorption markers for 7 years in a patient with malignant islet cell tumors. J Bone Miner Res (2002) 1.44
Endogenous prostaglandin D2 synthesis reduces an increase in plasminogen activator inhibitor-1 following interleukin stimulation in bovine endothelial cells. J Hypertens (2002) 1.43
Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension (2007) 1.43
Spontaneous remission of severe hyperparathyroidism with normalization of the reversed whole PTH/intact PTH ratio in a haemodialysis patient. Nephrol Dial Transplant (2007) 1.41
Contingent negative variations associated with command swallowing in humans. Clin Neurophysiol (2009) 1.41
Carvedilol ameliorates low-turnover bone disease in non-obese type 2 diabetes. Am J Nephrol (2011) 1.41
Serum pro-hepcidin as an indicator of iron status in dialysis patients. Ther Apher Dial (2008) 1.40
Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension (2003) 1.40
Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model. Lab Invest (2005) 1.38